Moleculin Biotech (MBRX) Net Cash Flow (2016 - 2025)
Moleculin Biotech (MBRX) posted quarterly Net Cash Flow of $2.1 million for Q4 2025, up 141.74% year-over-year from $877405.1 in Q4 2024, and up 350.12% quarter-over-quarter from -$848000.0 in Q3 2025.
Moleculin Biotech (MBRX) Net Cash Flow (2016 - 2025) Analysis & Trends
Moleculin Biotech's Net Cash Flow history runs 10 years deep, the most recent figure standing at $2.1 million for Q4 2025.
- In Q4 2025, Net Cash Flow rose 141.74% year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $4.5 million (up 123.64% YoY), while the FY2025 annual figure was $4.5 million, up 123.64% from the prior year.
- Net Cash Flow for Q4 2025 stood at $2.1 million, up from -$848000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $71.1 million in Q1 2021, with the low at -$8.1 million in Q2 2022.
- The 5-year median for Net Cash Flow is -$4.9 million (2022), against an average of -$314450.0.
- The sharpest annual moves came in 2021 and 2024: Net Cash Flow jumped 7093.93% in 2021, then slumped 396.77% in 2024.
- Moleculin Biotech's Net Cash Flow stood at -$4.3 million in 2021, then tumbled by 67.73% to -$7.3 million in 2022, then jumped by 85.9% to -$1.0 million in 2023, then plunged by 396.77% to -$5.1 million in 2024, then soared by 141.74% to $2.1 million in 2025.
- Business Quant data shows MBRX's Net Cash Flow at $2.1 million in Q4 2025, -$848000.0 in Q3 2025, and -$159000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.12 Mn |
| Dec 31, 2025 | 2.12 Mn |
| Sep 30, 2025 | -848,000.00 |
| Sep 30, 2025 | -848,000.00 |
| Jun 30, 2025 | -159,000.00 |
| Jun 30, 2025 | -159,000.00 |
| Mar 31, 2025 | 3.44 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Dec 31, 2024 | -5.08 Mn |
| Sep 30, 2024 | -1.45 Mn |
| Sep 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | -6.72 Mn |
| Mar 31, 2024 | -6.72 Mn |
| Dec 31, 2023 | -1.02 Mn |
| Dec 31, 2023 | -1.02 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Sep 30, 2023 | -7.58 Mn |